AstraZeneca: When externalisation becomes part of a business model

NEUTRAL, Fair Value 4860p vs. 4880p (+2%)
News published on April Monday 27, 2015
Share on

The pipeline is still advancing nicely but we see less reasons for excitement from the Q1 numbers and externalisation revenues as a new recurring part of the business model make us perplexed. We think the best advice for the moment is to stay NEUTRAL on the stock as we have no upside to our FV.

For more information, please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities